Kevin Jao

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Catherine Labbé, Michael Cabanero, Grzegorz Korpanty et al. · Lung Cancer · 2017 · 246 citations

Medicine, Pathology, Cancer Genomics +7

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier et al. · Journal of Thoracic Oncology · 2021 · 239 citations · Full text

High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

Arielle Elkrief, Antoine Desîlets, Neha Papneja et al. · European Journal of Cancer · 2020 · 80 citations · Full text

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau et al. · European Journal of Cancer · 2020 · 76 citations

Real-world Multicentre Study, Medicine, Historical Cohort +9

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Neal Ready, Clarisse Audigier-Valette, Jonathan W. Goldman et al. · Journal for ImmunoTherapy of Cancer · 2023 · 67 citations · Full text